This week I tackle an interesting cohort study that Jack Cush (@RheumNow) mentioned in his podcast. It's a nice opportunity to discuss bDMARDs in the "real world" (AKA Sweden). Follow me @ebrheum and let me know what you think of the episode!
Entries from August 2019
E45: TNF or TCZ or ABA or RTX: Real World Data for RA
August 29th, 2019 · Comments
Tags: DefaultTag
E44: SELECT-COMPARE Upadacitinib (JAKi) for Rheumatoid Arthritis
August 15th, 2019 · Comments
Finally got around to tackling the JAKi this week. I decided to focus on SELECT-COMPARE, which pitted upadacitinib (selective JAK1 inhibitor) against adalimumab and placebo. I briefly discuss other JAKs and my thoughts on the future of this area. Get the paper and others at ebrheum.com and follow me @ebrheum!
Tags: DefaultTag
E43: Tofacitinib for MDA5 Amyopathic Dermatomyositis ILD
August 8th, 2019 · Comments
Back this week to discuss an interesting paper in the NEJM. Lots of interesting issues, most notably historical controls and their limitations. Find all my work at ebrheum.com!
Tags: DefaultTag